The Long-Term Effect of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo-Controlled Trial

    May 2002 in “ The Journal of Urology
    ALVIN M. MATSUMOTO, LISA TENOVER, MICHAEL McCLUNG, DAVID MOBLEY, JACK GELLER, MICHAEL SULLIVAN, JOHN GRAYHACK, HUNTER WESSELLS, DOV KADMON, MALACHI FLANAGAN, GANG K. ZHANG, JOSEPH SCHMIDT, ALICE M. TAYLOR, MICHAEL LEE, JOANNE WALDSTREICHER
    Image of study
    TLDR Finasteride doesn't harm bone density in older men with BPH.
    This study examined the long-term effects of finasteride, a type II 5α-reductase inhibitor, on bone mineral density in men with benign prostatic hyperplasia. The study involved 157 patients who were randomized to receive either finasteride or a placebo for four years. The results showed that long-term inhibition of type II 5α-reductase with finasteride did not adversely affect bone mineral density. The study concluded that long-term inhibition of type II 5α-reductase with reduced dihydrotestosterone does not adversely affect bone mineral density in older men with BPH.
    Discuss this study in the Community →

    Research cited in this study

    5 / 5 results

    Related Community Posts Join

    6 / 1000+ results

      community Proof that finasteride messes with neurosteroids

      in Research/Science  230 upvotes 4 months ago
      Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 3 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 2 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    1 / 1 results